Modified Patent Hemostasis Strategy Based on the Platelet Counts for Transradial Access Chemoembolization in Patients with Hepatocellular Carcinoma: A Prospective Single-Center Study
Yin-Gen Luo, Xiao-Wu Zhang, Jiay-Wei Tsauo, Ying Li, Jin-Gui Li, Qing Peng, Ya-Wei Li, Wei Sun, He Zhao, Xiao Li Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Col...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-04-01
|
| Series: | Journal of Hepatocellular Carcinoma |
| Subjects: | |
| Online Access: | https://www.dovepress.com/modified-patent-hemostasis-strategy-based-on-the-platelet-counts-for-t-peer-reviewed-fulltext-article-JHC |
| _version_ | 1827960997714853888 |
|---|---|
| author | Luo YG Zhang XW Tsauo JW Li Y Li JG Peng Q Li YW Sun W Zhao H Li X |
| author_facet | Luo YG Zhang XW Tsauo JW Li Y Li JG Peng Q Li YW Sun W Zhao H Li X |
| author_sort | Luo YG |
| collection | DOAJ |
| description | Yin-Gen Luo, Xiao-Wu Zhang, Jiay-Wei Tsauo, Ying Li, Jin-Gui Li, Qing Peng, Ya-Wei Li, Wei Sun, He Zhao, Xiao Li Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of ChinaCorrespondence: Xiao Li; He Zhao, Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China, Tel/Fax +86 010 8778 8502, Email simonlixiao@gmail.com; hezhaoo@gmail.comObjective: This study aimed to investigate the shortest compression time to achieve hemostasis and the optimal hemostasis strategy in patients treated with transradial access chemoembolization (TRA-TACE).Methods: From October 2019 to October 2021, 119 consecutive patients with hepatocellular carcinoma (HCC) who underwent 134 sessions of TRA-TACE were included in this prospective single-center study. The compression time was measured by decompressing the device for 30 min, and thereafter, every 10 min after the procedure until complete hemostasis was achieved.Results: Technical success was achieved for all TRA procedures. None of the patients experienced major TRA-related adverse events. Minor adverse events occurred in 7.5% of the patients. The mean compression time was 31.8 ± 5.0 min. Factors that may impact hemostasis were analyzed by univariate and multivariate analyses, and a platelet count < 100× 109 /L (p = 0.016, odds ratio = 3.942) was found to be an independent factor that could predict the failure to achieve hemostasis within 30 min. For patients with a platelet count < 100× 109 /L, the compression time required to achieve hemostasis was 60 min. For patients with a platelet count ≥ 100× 109 /L, the compression time required to achieve hemostasis was 40 min.Conclusion: To achieve hemostasis in patients with HCC treated with TRA-TACE, compression for 60 min is sufficient for those with a platelet count < 100× 109 /L, and compression for 40 min is sufficient for those with a platelet count ≥ 100× 109 /L.Keywords: hepatocellular carcinoma, transarterial chemoembolization, transradial access, hemostasis |
| first_indexed | 2024-04-09T16:18:40Z |
| format | Article |
| id | doaj.art-dbe2568bae0b464abcbe848435a02639 |
| institution | Directory Open Access Journal |
| issn | 2253-5969 |
| language | English |
| last_indexed | 2024-04-09T16:18:40Z |
| publishDate | 2023-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Hepatocellular Carcinoma |
| spelling | doaj.art-dbe2568bae0b464abcbe848435a026392023-04-23T18:44:07ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692023-04-01Volume 1068769583228Modified Patent Hemostasis Strategy Based on the Platelet Counts for Transradial Access Chemoembolization in Patients with Hepatocellular Carcinoma: A Prospective Single-Center StudyLuo YGZhang XWTsauo JWLi YLi JGPeng QLi YWSun WZhao HLi XYin-Gen Luo, Xiao-Wu Zhang, Jiay-Wei Tsauo, Ying Li, Jin-Gui Li, Qing Peng, Ya-Wei Li, Wei Sun, He Zhao, Xiao Li Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of ChinaCorrespondence: Xiao Li; He Zhao, Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China, Tel/Fax +86 010 8778 8502, Email simonlixiao@gmail.com; hezhaoo@gmail.comObjective: This study aimed to investigate the shortest compression time to achieve hemostasis and the optimal hemostasis strategy in patients treated with transradial access chemoembolization (TRA-TACE).Methods: From October 2019 to October 2021, 119 consecutive patients with hepatocellular carcinoma (HCC) who underwent 134 sessions of TRA-TACE were included in this prospective single-center study. The compression time was measured by decompressing the device for 30 min, and thereafter, every 10 min after the procedure until complete hemostasis was achieved.Results: Technical success was achieved for all TRA procedures. None of the patients experienced major TRA-related adverse events. Minor adverse events occurred in 7.5% of the patients. The mean compression time was 31.8 ± 5.0 min. Factors that may impact hemostasis were analyzed by univariate and multivariate analyses, and a platelet count < 100× 109 /L (p = 0.016, odds ratio = 3.942) was found to be an independent factor that could predict the failure to achieve hemostasis within 30 min. For patients with a platelet count < 100× 109 /L, the compression time required to achieve hemostasis was 60 min. For patients with a platelet count ≥ 100× 109 /L, the compression time required to achieve hemostasis was 40 min.Conclusion: To achieve hemostasis in patients with HCC treated with TRA-TACE, compression for 60 min is sufficient for those with a platelet count < 100× 109 /L, and compression for 40 min is sufficient for those with a platelet count ≥ 100× 109 /L.Keywords: hepatocellular carcinoma, transarterial chemoembolization, transradial access, hemostasishttps://www.dovepress.com/modified-patent-hemostasis-strategy-based-on-the-platelet-counts-for-t-peer-reviewed-fulltext-article-JHCcarcinomahepatocellularchemoembolizationtherapeutichemostasisvascular access. |
| spellingShingle | Luo YG Zhang XW Tsauo JW Li Y Li JG Peng Q Li YW Sun W Zhao H Li X Modified Patent Hemostasis Strategy Based on the Platelet Counts for Transradial Access Chemoembolization in Patients with Hepatocellular Carcinoma: A Prospective Single-Center Study Journal of Hepatocellular Carcinoma carcinoma hepatocellular chemoembolization therapeutic hemostasis vascular access. |
| title | Modified Patent Hemostasis Strategy Based on the Platelet Counts for Transradial Access Chemoembolization in Patients with Hepatocellular Carcinoma: A Prospective Single-Center Study |
| title_full | Modified Patent Hemostasis Strategy Based on the Platelet Counts for Transradial Access Chemoembolization in Patients with Hepatocellular Carcinoma: A Prospective Single-Center Study |
| title_fullStr | Modified Patent Hemostasis Strategy Based on the Platelet Counts for Transradial Access Chemoembolization in Patients with Hepatocellular Carcinoma: A Prospective Single-Center Study |
| title_full_unstemmed | Modified Patent Hemostasis Strategy Based on the Platelet Counts for Transradial Access Chemoembolization in Patients with Hepatocellular Carcinoma: A Prospective Single-Center Study |
| title_short | Modified Patent Hemostasis Strategy Based on the Platelet Counts for Transradial Access Chemoembolization in Patients with Hepatocellular Carcinoma: A Prospective Single-Center Study |
| title_sort | modified patent hemostasis strategy based on the platelet counts for transradial access chemoembolization in patients with hepatocellular carcinoma a prospective single center study |
| topic | carcinoma hepatocellular chemoembolization therapeutic hemostasis vascular access. |
| url | https://www.dovepress.com/modified-patent-hemostasis-strategy-based-on-the-platelet-counts-for-t-peer-reviewed-fulltext-article-JHC |
| work_keys_str_mv | AT luoyg modifiedpatenthemostasisstrategybasedontheplateletcountsfortransradialaccesschemoembolizationinpatientswithhepatocellularcarcinomaaprospectivesinglecenterstudy AT zhangxw modifiedpatenthemostasisstrategybasedontheplateletcountsfortransradialaccesschemoembolizationinpatientswithhepatocellularcarcinomaaprospectivesinglecenterstudy AT tsauojw modifiedpatenthemostasisstrategybasedontheplateletcountsfortransradialaccesschemoembolizationinpatientswithhepatocellularcarcinomaaprospectivesinglecenterstudy AT liy modifiedpatenthemostasisstrategybasedontheplateletcountsfortransradialaccesschemoembolizationinpatientswithhepatocellularcarcinomaaprospectivesinglecenterstudy AT lijg modifiedpatenthemostasisstrategybasedontheplateletcountsfortransradialaccesschemoembolizationinpatientswithhepatocellularcarcinomaaprospectivesinglecenterstudy AT pengq modifiedpatenthemostasisstrategybasedontheplateletcountsfortransradialaccesschemoembolizationinpatientswithhepatocellularcarcinomaaprospectivesinglecenterstudy AT liyw modifiedpatenthemostasisstrategybasedontheplateletcountsfortransradialaccesschemoembolizationinpatientswithhepatocellularcarcinomaaprospectivesinglecenterstudy AT sunw modifiedpatenthemostasisstrategybasedontheplateletcountsfortransradialaccesschemoembolizationinpatientswithhepatocellularcarcinomaaprospectivesinglecenterstudy AT zhaoh modifiedpatenthemostasisstrategybasedontheplateletcountsfortransradialaccesschemoembolizationinpatientswithhepatocellularcarcinomaaprospectivesinglecenterstudy AT lix modifiedpatenthemostasisstrategybasedontheplateletcountsfortransradialaccesschemoembolizationinpatientswithhepatocellularcarcinomaaprospectivesinglecenterstudy |